The 2026 ASBMR Symposium and the ASBMR/RBDA 2026 Symposium will be held on Thursday, October 8, 2026, one day prior the 2026 Annual Meeting, at the John B. Hynes Veterans Memorial Convention Center in Boston, Massachusetts, USA. Learn more about the goals of each meeting and view the full program.
2026 ASBMR Pre-Meeting Symposium on Biological Control of Bone Quality: Mechanisms and Therapies
2026 ASBMR/RBDA Pre-Meeting Symposium on Translating Mechanisms to Medicine: Advances in Rare Bone Diseases
The goal of the 2026 ASBMR Pre-Meeting Symposium on Biological Control of Bone Quality: Mechanisms and Therapies is to advance the scientific understanding of the biological, mechanical, and material mechanisms that determine bone quality. It will also aim to accelerate translation of bone quality research into improved diagnostic, predictive, and therapeutic strategies for skeletal fragility.
| Session 1: Unmet Clinical Needs to Diagnose and Treat Bone Quality | 9:00 am - 10:30 am |
| Introduction |
TBA |
| Diabetes |
TBA |
| Aging |
TBA |
| Metabolic Bone Disease: From Rare to Common |
TBA |
| Talk from Submitted Abstracts |
TBA |
| Break | 10:30 am - 10:45 am |
| Session 2: Mechanometabolic Control of Bone Quality | 10:45 am - 12:15 pm |
| The Role of Osteocytes |
TBA |
| Osteocytes and Material Properties |
|
| Talk from submitted abstracts |
TBA |
| Talk from submitted abstracts |
TBA |
| Lunch and Poster Viewing |
| Session 3: Emerging Technologies in Bone Quality Assessment | 1:00 pm - 2:00 pm |
| Ulnar Vibration |
TBA |
| Osteoprobe |
TBA |
| Tibia Ultrasound |
TBA |
| Transcutaneous Raman |
TBA |
| Break | 2:00 pm - 2:15 pm |
| Session 4: Bone Quality Diagnostics | 2:15 pm - 3:45 pm |
| New Ways of Looking at Bone Matrix Quality in Osteocytes |
TBA |
| Genetic Architecture of Bone Quality |
TBA |
| Towards Serum Biomarkers for Bone Quality |
TBA |
| Water Content in Bone |
TBA |
| Talk from Submitted Abstracts |
| Break |
| Session 5: Novel Bone Quality Indicators & Therapeutics | 4:00 pm - 5:30 pm |
| Regulation on Bone Quality with the Microbiome |
TBA |
| Profiling the Ideal Drug to Improve Bone Quality |
TBA |
| Technology/Serum Markers |
TBA |
| Wrap Up & Next Steps |
TBA |
| Session 6: Poster Session & Reception | 5:30 pm - 6:30 pm |
The 2026 ASBMR/RBDA Pre-Meeting Symposium on Translating Mechanisms to Medicine: Advances in Rare Bone Diseases will feature a diverse group of speakers including patients, researchers from academia and industry, and government officials to discuss the effectiveness and design of rare bone disease therapeutics.
| Session 1: From Discovery to Delivery: Advancing Rare Bone Disease Therapies Across the Entire Innovation Spectrum | 9:00 am - 10:45 am |
| 9:00 am - 9:15 am |
Introduction to Symposium/SIG Introduction |
TBA |
| 9:15 am - 9:40 am |
From Mechanism to Medicine: The Therapeutic Journey in Rare Bone Disease |
TBA |
| 9:40 am - 9:55 am |
Registries as Engines of Discovery |
TBA |
| 9:55 am - 10:20 am |
Customizing Clinical Trial Design to Rare Disorders |
TBA |
| 10:20 am - 10:45 am |
Talk from Submitted Abstracts |
TBA |
| 10:45 am - 11:00 am |
Break |
| Session 2: The Parathyroid Hormone Pathway: From Emerging Mechanisms to Evolving Therapeutics | 11:00 am - 12:20 pm |
| 11:00 am - 11:25 am |
Engineering PTH Replacement: Molecular, Biologic, and Delivery Innovations in Hypoparathyroidism |
TBA |
| 11:25 am - 11:50 am |
The Expanding Landscape of PTHR1‑Related Disorders: New Mechanisms and New Diagnose |
TBA |
| 11:50 am - 12:05 pm |
Beyond GNAS: Evolving Understanding of Epigenetic Disorders in PTH Resistance |
TBA |
| 12:05 pm - 12:20 pm |
Talk from Submitted Abstract |
TBA |
| 12:30 pm - 1:30 pm |
Lunch and Poster Viewing |
| Session 3: Next‑Generation Tools Transforming Rare Bone Disease Research | 1:30 pm - 3:00 pm |
| 1:30 pm - 1:55 pm |
Changing Lives by Changing DNA: Interventions for Rare Skeletal Conditions |
TBA |
| 1:55 pm - 2:20 pm |
AI-Driven Strategies for Discovering and Repurposing Therapies in Rare Diseases |
TBA |
| 2:20 pm - 2:45 pm |
Patient Specific IPSC to Identify Therapeutic Avenues for Rare Bone Disorders |
TBA |
| 2:45 pm - 3:00 pm |
Talk from Submitted Abstracts |
TBA |
| 2:30 pm - 3:00 pm |
Break |
| Session 4: It Takes an Ecosystem: The Strategic Partnerships to Unlock Rare Disease Innovation | 3:15 pm - 5:00 pm |
| 3:15 pm - 3:40 pm |
Regulatory Pathways and Patient Voices: An FDA Perspective on Rare Bone Disease Innovation |
TBA |
| 3:40 pm - 4:05 pm |
The Collaboration Imperative: Patients, Innovators, and Industry Working Together for Rare Diseases |
TBA |
| 4:05 pm - 4:20 pm |
Uniting Voices, Aligning Missions: How Advocacy Leaders Build the Coalitions That Change Rare Disease Trajectories |
TBA |
| 4:20 pm - 5:00 pm |
Patient Organization Portal |
TBA |
| 5:00 pm - 5:15 pm |
Wrap-Up |
| 5:15 pm - 6:30 pm |
Poster Session and Reception |
The ASBMR gratefully acknowledges the following companies for their educational grant support: Alexion, AstraZeneca Rare Disease, Ascendis Pharma, BioMarin Pharmaceutical Inc., BridgeBio Pharma, Inc., Inozyme Pharma, Ipsen Biopharmaceuticals Inc., Kyowa Kirin, Inc., and Ultragenyx Pharmaceutical Inc.